Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 2

Changes in anthropometric measurements and blood pressure.

Parameters	Group	0 month	12 months	P-value	Difference	P-value
Body mass index (kg/m^2)	T	29.2±5.8	29.0±5.9	0.875	−0.2±1.1
	L	27.8±3.8	28.1±4.2	0.398	0.3±0.8	0.447
Waist circumference (cm)	T	97.0±14.9	98.2±15.5	0.247	1.3±3.4
	L	94.4±8.1	99.6±8.6	0.091	5.3±7.8	0.310
Hip circumference (cm)	T	111.9±20.9	107.9±15.0	0.500	−2.1±8.3
	L	99.6±8.7	98.3±9.1	0.655	−0.1±0.4	0.754
Systolic blood pressure (mmHg)	T	139.4±11.1	130.8±15.0	0.045	−8.6±15.2
	L	136.4±13.9	127.4±10.6	0.046	−9.0±10.4	0.933
Diastolic blood pressure (mmHg)	T	86.0±8.5	75.4±12.7	0.032	−10.6±13.7
	L	81.6±13.0	75.3±7.9	0.116	−6.3±9.1	0.446
Pulse (beats/min)	T	74.5±11.8	73.2±9.4	0.397	−1.2±5.8
	L	85.0±9.5	76.4±11.5	0.273	−5.0±10.2	0.397

Data are presented as mean ± SD. Parameters at 0 and 12 months of treatment were compared by Wilcoxon's matched-pair signed-rank test. Differences are shown as [value at 12 months − value at 0 month]. Differences between groups (telmisartan (T) versus losartan (L)) were compared by Mann-Whitney 𝑈 test.